Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
G
G. Johansen, Chelsea
Colorado School of Mines
(
T0930-02-09
)
Polyplex Particle Size Alters Transgene Expression and Cell Viability in a Cell Type-Dependent Manner
Chelsea G. Johansen
Favorite
Gallegos, Austin
AstraZeneca
(
T1030-02-07
)
Viscosity Reduction of an IgG1 Antibody via Hydrogen-Deuterium Exchange Mass Spectrometry-Augmented Protein Engineering
Austin Gallegos
Favorite
Gambardella, Janice
Boehringer Ingelheim
(
T1030-02-08
)
Systematic Optimization of ADA Assays for Complex Biologics: A Framework for Addressing Assay Challenges Across Modalities
Janice Gambardella
Favorite
Gao, Chan
Genentech, Inc.
(
M1030-02-07
)
Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Chan Gao
Favorite
Gaudet, Suzanne
Novartis
(
T1230-02-08
)
Reverse Translational Modeling for Early Benchmarking of Clinically Active Doses from In Vitro Cell Killing and T-Cell Activation Data for BCMAxCD3 T-Cell Engagers
Suzanne Gaudet
Favorite
Gawalt, Ellan
Duquesne University
(
T0930-01-04
)
Zinc-Associated Peptide Coacervates for Recombinant Protein Capture and Release
Ellan Gawalt
Favorite
Gemeinhart, Richard
University of Illinois Chicago
(
M0930-01-04
)
Macroporous Granular Nanocomposite Hydrogels for Controlled Oligonucleotide Delivery
Richard Gemeinhart
Favorite
Ghosh, Santaneel
Southeast Missouri State University
(
M0930-01-03
)
Antiproliferative Effects of Low Level Light-Low Dose Magnetic Nanoparticle Exposure on Human Umbilical Vein Endothelial Cells
Santaneel Ghosh
Favorite
Ghugari, Rahul
Custom Biologics
(
T0930-02-08
)
Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Rahul Ghugari
Favorite
Goihberg, Polina
Pfizer Inc.
(
M1330-02-06
)
Establishing Cellular Mechanisms Underlying Species-Related Differences in the Effective Delivery of LNP-mRNA to Overcome Limitations of Human Dose Translation
Polina Goihberg
Favorite
Gomes, Conor
Pion Inc.
(
M1130-02-08
)
Conserving Biorelevant Enzymatic Activity during In Vitro Analysis of Biotransformable Drugs
Conor Gomes
Favorite
Goodall, Carlie
Custom Biologics
(
T0930-02-08
)
Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Carlie Goodall
Favorite
Goodman, Joanne
Celerion
(
M1530-02-06
)
Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies
Joanne Goodman
Favorite
Gopal, Kausy
Custom Biologics
(
T0930-02-08
)
Validation of an Anti-Drug Antibody Assay Against an Oncolytic Virus Immunotherapeutic
Kausy Gopal
Favorite
Grafelman, Daryl
Celerion
(
M1530-02-06
)
Improving Drug Tolerance in Anti-Drug Antibody (ADA) Assay using PandA Method – Case Studies
Daryl Grafelman
Favorite
Grall, Franck
BioAgilytix
(
M1330-02-09
)
Qualification of a Novel Multiplex Assay for the Quantitation of Chemokine Markers in Human Plasma and CSF Samples
Franck Grall
Favorite
(
T1030-02-06
)
Qualification of the S-PLEX Neurology Panel 1 (GFAP, NfL and Tau) MSD Assay
Franck Grall
Favorite
Grandas, Oscar
University of Tennessee
(
M1430-01-03
)
Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Oscar Grandas
Favorite
(
T1430-01-04
)
Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Oscar Grandas
Favorite
Grimsley, Lauren
University of Tennessee
(
M1430-01-03
)
Enhanced Membrane Composition for Lipid Nanoparticle Vascular Drug Delivery
Lauren Grimsley
Favorite
(
T1430-01-04
)
Long-Term Storage of Targeted Lipid Nanoparticles for Vascular Gene Therapies
Lauren Grimsley
Favorite
Grosskopf, Abigail
Genentech, Inc.
(
M1030-02-07
)
Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Abigail Grosskopf
Favorite
Gulianello, Michael
Sanofi
(
T1130-02-08
)
Evaluation of the MSD S-Plex Neuropanel 1 Multiplex Assay for Neurological Biomarkers
Michael Gulianello
Favorite
Guo, Jeremy
WuXi Biologics
(
T1230-01-03
)
Break Loose Force and Glide Force Evaluation of Various Container Closure System Combination for Empty Syringe
Jeremy Guo
Favorite
Guo, Jinglong
Genentech, Inc.
(
M1030-02-07
)
Pharmacokinetic/Pharmacodynamic Insights into VSIG4 Degrading Antibodies
Jinglong Guo
Favorite
Gupta, Swati
AbbVie Inc.
(
M0930-02-08
)
Fit for Purpose Qualified Assays to Assess Exploratory Biomarkers in Human Aqueous Humor to Unveil Target Engagement and Pharmacological Activity in Complement Factor C5 Inhibition Clinical Studies
Swati Gupta
Favorite
Gurumoorthy, Viswanathan
Merck & Co., Inc.
(
M1330-01-01
)
Utility of Small Angle X-Ray Scattering (SAXS) in Process Development, Characterization and Comparability of Lipid Nanoparticles, Liposomes and Fusion Proteins
Viswanathan Gurumoorthy
Favorite
Gurvich, Vadim J.
University of Minnesota
(
T1230-01-05
)
Impact of Excipient Composition on the Stability of Trastuzumab Biosimilars
Vadim J. Gurvich
Favorite
